AN UNBIASED VIEW OF LENMELDY

The FDA assessed the protection and performance of atidarsagene autotemcel based on info from 37 small children who received atidarsagene autotemcel in two single-arm, open-label clinical trials and in an expanded entry application.[seven] Children who acquired treatment method with atidarsagene autotemcel ended up compared to untreated youngsters